19 December 2024 : Clinical Research
Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes
Wei Li ACDE 1*, Yi Li BEF 2, Chen Liu DE 1, Jinghao Yuan BCDE 1, Weize Fan CDEF 1, Qing Miao BEF 1, Xinshun Gu ADE 1DOI: 10.12659/MSM.945457
Med Sci Monit 2024; 30:e945457
Table 1 Clinical characteristics of participants at baseline.
| Characteristic | Aspirin group (n=84) | Aspirin + rivaroxaban group (n=84) | P value |
|---|---|---|---|
| Age (year) | 61.96±7.52 | 60.31±7.74 | 0.217 |
| Gender | 0.527 | ||
| Male | 53 (63.1%) | 49 (58.33%) | |
| Female | 31 (36.9%) | 35 (41.67%) | |
| BMI (kg/m) | 24.46±3.28 | 23.66±3.66 | |
| Smoking | 45 (53.57%) | 47 (55.95%) | 0.822 |
| Drink | 48 (57.14%) | 43 (51.19%) | 0.439 |
| Comorbidities | |||
| Hypertension | 51 (60.71%) | 56 (66.67%) | 0.422 |
| Diabetes | 27 (32.14%) | 32 (38.1%) | 0.419 |
| Chronic obstructive pulmonary disease | 11 (13.1%) | 9 (10.71%) | 0.634 |
| CK (u/l) | 272.28±34.05 | 263.88±35.09 | 0.117 |
| cTnT (ug/ml) | 68.16±7.55 | 67.41±11.48 | 0.618 |
| NT-proBNP (pg/ml) | 351.21±49.98 | 347.44±51.92 | 0.632 |
| History of acute myocardial infarction | 62 (73.81%) | 59 (70.24%) | 0.606 |
| History of multiple branches and segments of coronary artery lesions | 55 (65.48%) | 54 (64.29%) | 0.872 |
| Number of supports | 0.976 | ||
| ALT (U/L) | 54.17±8.6 | 55.38±9.64 | 0.392 |
| AST (U/L) | 25.55±5.3 | 25.24±6.08 | 0.533 |
| Medication | |||
| ACE inhibitor or ARB | 56 (66.67%) | 58 (69.05%) | 0.741 |
| Calcium-channel blocker | 21 (25%) | 19 (22.62%) | 0.717 |
| Diuretic | 23 (27.38%) | 24 (28.57%) | 0.864 |
| Beta-blocker | 55 (65.48%) | 59 (70.24%) | 0.509 |
| Lipid-lowering agent | 84 (100%) | 84 (100%) | |
| NSAID | 84 (100%) | 84 (100%) | |
| Non-trial PPI | 30 (35.71%) | 27 (32.14%) | 0.625 |
| BMI – body mass index; CK – creatine kinase; cTnT – cardiac troponin; NT-proBNP – N-terminal fragment B-type natriuretic peptide; ALT – alanine aminotransferase; AST – aspartate aminotransferase; ACE – angiotensin converting enzyme; ARB – angiotensin receptor blocker; NSAID – nonsteroidal anti-inflammatory drugs; PPI – proton pump inhibitors. | |||